Storia della carriera di Mitchell Golbus
Precedenti posizioni note di Mitchell Golbus
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Diamics, Inc.
 Diamics, Inc. Medical SpecialtiesHealth Technology Diamics Inc. is a medical technology company located in the San Francisco Bay Area. As an innovator in women’s health, the company develops breakthrough cancer diagnostic systems. Diamics’ management team has an extensive track record of success in the medical device, diagnostics and biotechnology industries. The company’s mission is to constantly improve cancer screening diagnostics and provide solutions for unmet medical needs in women’s health. Diamics has two products in near term (6-12 months) development timelines. One product, the TouchPap™, focuses on improving the ubiquitous Pap test and is scheduled for launch in 2009. Following on the heels of this launch will be products aimed at the rapidly expanding molecular diagnostics market, specifically targeting HPV and cervical cancer. | Direttore Tecnico/Scientifico/R&S | 09/11/2009 | 15/10/2013 |
| Presidente | 09/11/2009 | 15/10/2013 | |
| The University of California, San Francisco | Corporate Officer/Principal | 01/01/1981 | 01/01/1994 |
Formazione di Mitchell Golbus
| University of Illinois | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
Posizioni
| Chief Tech/Sci/R&D Officer | 1 |
| President | 1 |
| Doctorate Degree | 1 |
Settori
| Consumer Services | 3 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Diamics, Inc.
Diamics, Inc. Medical SpecialtiesHealth Technology Diamics Inc. is a medical technology company located in the San Francisco Bay Area. As an innovator in women’s health, the company develops breakthrough cancer diagnostic systems. Diamics’ management team has an extensive track record of success in the medical device, diagnostics and biotechnology industries. The company’s mission is to constantly improve cancer screening diagnostics and provide solutions for unmet medical needs in women’s health. Diamics has two products in near term (6-12 months) development timelines. One product, the TouchPap™, focuses on improving the ubiquitous Pap test and is scheduled for launch in 2009. Following on the heels of this launch will be products aimed at the rapidly expanding molecular diagnostics market, specifically targeting HPV and cervical cancer. | Health Technology |
- Borsa valori
- Insiders
- Mitchell Golbus
- Esperienza
